In the case of G-CSF, the last double-blind placebo controlled randomized study performed in 2006 showed that the administration of G-CSF during postoperative radiotherapy for head and neck cancer exhibits a tendency to lower the rates of percutaneous endoscopic gastrostomy placement and the severity of oral mucositis, but these effects were not statistically significant [113]. This evidence concerns the gene CSF3 and mucositis.